Therapy Algorithm for Portal Vein Thrombosis in Liver Cirrhosis: The Internist's Point of View.

Viszeralmedizin Pub Date : 2014-12-01 DOI:10.1159/000370053
Martin Rössle, Birke Bausch, Christoph Klinger
{"title":"Therapy Algorithm for Portal Vein Thrombosis in Liver Cirrhosis: The Internist's Point of View.","authors":"Martin Rössle,&nbsp;Birke Bausch,&nbsp;Christoph Klinger","doi":"10.1159/000370053","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Treatment of non-malignant portal vein thrombosis (PVT) in patients with cirrhosis has been neglected in the past because of the fear of bleeding complications when using anticoagulation and due to the technical difficulties associated with the implantation of the transjugular intrahepatic portosystemic shunt (TIPS). However, PVT has a negative impact on outcome and compromises liver transplantation, warranting treatment by using anticoagulation and TIPS.</p><p><strong>Methods: </strong>This review considers studies on the treatment of PVT in cirrhosis published in the last 10 years. Unfortunately, many of these studies are limited by their retrospective design and a small sample size.</p><p><strong>Results: </strong>Anticoagulation using low-molecular-weight heparin (LMWH) or vitamin K antagonists is effective in the treatment of patients with limited and recent PVT, resulting in a recanalization in up to 50% of the patients. TIPS (plus local measures) results in a recanalization of up to 100% and reduces the rebleeding rate considerably in patients with recent or chronic PVT.</p><p><strong>Conclusion: </strong>Based on the presently limited knowledge, a therapy algorithm is suggested favouring the TIPS as a first-line treatment for PVT in patients with symptomatic portal hypertension. Patients with thus far asymptomatic portal hypertension may first receive anticoagulation, preferably using LMWH. If these patients have a condition where anticoagulation is not promising (complete, extended, chronic PVT) or ineffective, or if they are candidates for liver transplantation, the TIPS may be implanted without delay.</p>","PeriodicalId":49114,"journal":{"name":"Viszeralmedizin","volume":"30 6","pages":"401-8"},"PeriodicalIF":0.0000,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000370053","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Viszeralmedizin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000370053","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 13

Abstract

Background: Treatment of non-malignant portal vein thrombosis (PVT) in patients with cirrhosis has been neglected in the past because of the fear of bleeding complications when using anticoagulation and due to the technical difficulties associated with the implantation of the transjugular intrahepatic portosystemic shunt (TIPS). However, PVT has a negative impact on outcome and compromises liver transplantation, warranting treatment by using anticoagulation and TIPS.

Methods: This review considers studies on the treatment of PVT in cirrhosis published in the last 10 years. Unfortunately, many of these studies are limited by their retrospective design and a small sample size.

Results: Anticoagulation using low-molecular-weight heparin (LMWH) or vitamin K antagonists is effective in the treatment of patients with limited and recent PVT, resulting in a recanalization in up to 50% of the patients. TIPS (plus local measures) results in a recanalization of up to 100% and reduces the rebleeding rate considerably in patients with recent or chronic PVT.

Conclusion: Based on the presently limited knowledge, a therapy algorithm is suggested favouring the TIPS as a first-line treatment for PVT in patients with symptomatic portal hypertension. Patients with thus far asymptomatic portal hypertension may first receive anticoagulation, preferably using LMWH. If these patients have a condition where anticoagulation is not promising (complete, extended, chronic PVT) or ineffective, or if they are candidates for liver transplantation, the TIPS may be implanted without delay.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
内科医生对肝硬化门静脉血栓形成的治疗方法
背景:肝硬化患者非恶性门静脉血栓形成(PVT)的治疗在过去一直被忽视,因为使用抗凝剂时担心出血并发症,以及由于经颈静脉肝内门静脉系统分流术(TIPS)植入的技术困难。然而,PVT对预后有负面影响,并危及肝移植,需要使用抗凝和TIPS治疗。方法:回顾近10年来肝硬化PVT治疗的相关研究。不幸的是,这些研究中的许多都受到回顾性设计和小样本量的限制。结果:使用低分子肝素(LMWH)或维生素K拮抗剂抗凝治疗局限性和近期PVT患者有效,导致高达50%的患者再通。TIPS(加上局部措施)可使近期或慢性PVT患者的再通率高达100%,并显著降低再出血率。结论:基于目前有限的知识,建议将TIPS作为对症门静脉高压患者PVT的一线治疗方法。迄今无症状的门静脉高压症患者可首先接受抗凝治疗,最好使用低分子肝素。如果这些患者的抗凝治疗没有希望(完全性、延续性、慢性PVT)或无效,或者他们是肝移植的候选者,TIPS可以立即植入。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Viszeralmedizin
Viszeralmedizin GASTROENTEROLOGY & HEPATOLOGY-SURGERY
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊最新文献
How Effective Are Percutaneous Liver-Directed Therapies in Patients with Non-Colorectal Liver Metastases? Arterial Therapies of Non-Colorectal Liver Metastases. Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer. Ectopic Spleen Tissue – an Underestimated Differential Diagnosis of a Hypervascularised Liver Tumour Precision Medicine and Non-Colorectal Cancer Liver Metastases: Fiction or Reality?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1